How Does Colon Cancer Transform into a Version Capable of Invading the Liver?

SadaNews - Cancer does not only seem dangerous because it grows inside the body, but because it sometimes knows how to leave its place. In the case of colorectal cancer specifically, the disease may start in the intestinal wall, but the critical moment occurs when some cells succeed in detaching from the original tumor, entering the bloodstream, reaching the liver, and forming new tumors there.

This small yet significant journey is what makes some cases of cancer more difficult to treat. Metastasis of colon cancer to the liver doesn't just indicate a new location for the disease but signifies entering a more complex stage, where controlling the tumor becomes harder, and the treatment plan requires surgery, precise medications, and long-term monitoring.

The World Health Organization indicates that in 2022, colorectal cancer recorded around 1.9 million new cases and over 900 thousand deaths worldwide, making it one of the heaviest cancer burdens on public health and the second leading cause of cancer-related death globally. The organization emphasizes that early screening and detection of tumors before their spread remain among the most important tools for reducing mortality.

Spread of Cells

Amid this scenario, a recent study by researchers from Weill Cornell Medicine and the Massachusetts Institute of Technology sheds light on the question: why do some colon cancer cells transform into cells capable of migrating and spreading, while others remain confined to the original tumor?

The study, featured on ScienceDaily, suggests that the secret may not only lie in a new genetic mutation but in changing the way genes are activated within the cell.

The key here is a transcription factor called GATA6. Its role can be simplified to being akin to a "guardian of identity" within the intestinal lining cells; it helps them maintain their original nature and function.

When levels of this factor decrease, cancer cells begin to abandon their usual identity and shift into a more primitive and flexible state, somewhat resembling embryonic cells capable of adapting and moving.

This flexibility is scientifically termed "cellular plasticity," and in a normal body, it may be beneficial; it helps cells repair tissues after injuries or adapt to stress. However, in cancer, the same feature can turn into a risk. A cell that becomes more flexible may become better able to escape its location, survive in the bloodstream, and then settle in a new organ.

In this study, researchers relied on tumor organoids, which are three-dimensional clusters of cancer cells grown in the lab that mimic some characteristics of real tumors. They then implanted these organoids into the intestines of mice to monitor the early stages at which cells acquire the ability to move. They found that reduced GATA6 levels were associated with the emergence of cells with a greater capacity to reach the liver and establish new metastases.

Most importantly, deleting GATA6 in animal models increased the burden of liver metastases, while its impact on the growth of the original tumor itself was not significant. This is a profoundly significant point; it suggests that the risk is not always measured by the size or speed of the tumor but sometimes by what happens inside the cell in terms of changes in identity and behavior.

The researchers also noted that cells that lost GATA6 tended to shift from a positive state for the LGR5 marker to a negative state for this marker, a condition previously associated with a higher ability to initiate liver metastases. In simpler terms, we are not just talking about a tumor growing but about cells learning how to become more prepared to leave.

These findings open an important door for precision medicine. If it is proven in the future that decreased GATA6 can signal a tumor's propensity to spread, it may help doctors identify patients who need closer monitoring or more intensive treatment even before metastases become clearly visible.

It may also encourage researchers to develop treatments that do not only target killing cancer cells but prevent them from shedding their identity and entering the flexible state that grants them the ability to spread.

Promising Step

However, it is important not to exaggerate; this study does not provide a ready-made treatment for colon cancer patients, nor does it mean that testing GATA6 will become part of every diagnostic protocol tomorrow. It is an important research step in understanding the mechanism of transition and still requires broader studies and testing the feasibility of using GATA6 as a marker or therapeutic target in humans.

The true value of the study is that it alters the way of thinking about cancer. Instead of focusing solely on the traditional question: what mutation caused the tumor? the new question becomes: how does the cell change its character? And when does it abandon its quiet identity to become a dangerous traveler in the blood?

Source: Foreign Press